Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation
Aim Alemtuzumab is a monoclonal antibody used as induction immunosuppressive therapy in kidney transplantation. It targets CD52 on lymphocytes, inducing profound immune cell depletion upon administration. Owing to its off‐label status in kidney transplantation, its pharmacokinetic characteristics are largely unknown in this setting, and its current fixed dosing algorithm originates from other populations. We developed a population pharmacokinetic model for alemtuzumab in kidney transplant recipients and investigated the potential of personalized alemtuzumab therapy. Methods In total, 362 pharmacokinetic observations drawn 0‐165 days after transplantation were available from 61 adult kidney transplant recipients who received two consecutive doses of 15 mg alemtuzumab subcutaneously. A population pharmacokinetic model was developed using nonlinear mixed‐effects modelling and applied to simulate various dosing regimens. Results The alemtuzumab concentration‐time data were best described by a two‐compartmental model with first‐order absorption and parallel first‐order and time‐varying concentration‐dependent elimination, with between‐subject variability on the first‐order elimination (39.6%) and central distribution volume (39.6%). Alemtuzumab pharmacokinetics varied with body size, rendering lighter individuals exposed to lympholytic alemtuzumab concentrations (>0.1 mg/L) for prolonged durations as compared to their heavier peers. This between‐subject variability could be reduced through lean bodyweight‐adjusted dosing, showing a twofold to threefold reduction in the slope of the median alemtuzumab exposure over the bodyweight range. Conclusion Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalized treatment strategy. Lean bodyweight‐adjusted dosing poses an option for individualized dosing, but further evaluation of its potential clinical benefit is warranted..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
British Journal of Clinical Pharmacology - 89(2023), 4, Seite 1471-1485 |
| Beteiligte Personen: |
Zwart, Tom C. [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 The British Pharmacological Society |
|---|
| Umfang: |
15 |
|---|
| doi: |
10.1111/bcp.15608 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015147460 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015147460 | ||
| 003 | DE-627 | ||
| 005 | 20231111131732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bcp.15608 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_BCP_2023_89_4.zip.xml |
| 035 | |a (DE-627)WLY015147460 | ||
| 035 | |a (WILEY)BCP15608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Zwart, Tom C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation |
| 264 | 1 | |c 2023 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 The British Pharmacological Society | ||
| 520 | |a Aim Alemtuzumab is a monoclonal antibody used as induction immunosuppressive therapy in kidney transplantation. It targets CD52 on lymphocytes, inducing profound immune cell depletion upon administration. Owing to its off‐label status in kidney transplantation, its pharmacokinetic characteristics are largely unknown in this setting, and its current fixed dosing algorithm originates from other populations. We developed a population pharmacokinetic model for alemtuzumab in kidney transplant recipients and investigated the potential of personalized alemtuzumab therapy. Methods In total, 362 pharmacokinetic observations drawn 0‐165 days after transplantation were available from 61 adult kidney transplant recipients who received two consecutive doses of 15 mg alemtuzumab subcutaneously. A population pharmacokinetic model was developed using nonlinear mixed‐effects modelling and applied to simulate various dosing regimens. Results The alemtuzumab concentration‐time data were best described by a two‐compartmental model with first‐order absorption and parallel first‐order and time‐varying concentration‐dependent elimination, with between‐subject variability on the first‐order elimination (39.6%) and central distribution volume (39.6%). Alemtuzumab pharmacokinetics varied with body size, rendering lighter individuals exposed to lympholytic alemtuzumab concentrations (>0.1 mg/L) for prolonged durations as compared to their heavier peers. This between‐subject variability could be reduced through lean bodyweight‐adjusted dosing, showing a twofold to threefold reduction in the slope of the median alemtuzumab exposure over the bodyweight range. Conclusion Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalized treatment strategy. Lean bodyweight‐adjusted dosing poses an option for individualized dosing, but further evaluation of its potential clinical benefit is warranted. | ||
| 700 | 1 | |a Bezstarosti, Suzanne |4 aut | |
| 700 | 1 | |a Achini, Federica R. |4 aut | |
| 700 | 1 | |a Reinders, Marlies E. J. |4 aut | |
| 700 | 1 | |a Schilham, Marco W. |4 aut | |
| 700 | 1 | |a Heidt, Sebastiaan |4 aut | |
| 700 | 1 | |a Guchelaar, Henk‐Jan |4 aut | |
| 700 | 1 | |a Fijter, Johan W. |4 aut | |
| 700 | 1 | |a Moes, Dirk Jan A. R. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Clinical Pharmacology |g 89(2023), 4, Seite 1471-1485 |w (DE-627)WLY00261751X |x 13652125 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2023 |g number:4 |g pages:1471-1485 |g extent:15 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2023 |e 4 |h 1471-1485 |g 15 | ||